Affimed to Present at the Jefferies 2017 London Healthcare Conference
November 15 2017 - 3:01AM
Heidelberg, Germany, November 15, 2017 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies, announced today that Dr. Adi Hoess, CEO, will
present at the Jefferies 2017 London Healthcare Conference on
Wednesday, November 15, 2017, at 4:00 pm GMT.
A live webcast of the conference presentation
can be accessed through the "Events" section on the "Investors
& Media" page of the Affimed website at
www.affimed.com/events.php. A replay of the presentation will be
available from Affimed's website for 30 days following the
conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK and T cells). We are developing
single and combination therapies to treat cancers and other
life-threatening diseases. For more information, please visit
www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IRPhone: +49 6221
64793341E-Mail: a.alexandru@affimed.com, IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2024 to May 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From May 2023 to May 2024